-
Is Fecal Immunochemical Testing the Right FIT for Patients With Symptoms?
In their recent Gastroenterology editorial, Dr. Audrey H. Calderwood (Dartmouth-Hitchcock Medical Center) and Dr. Theodore R. Levin (Kaiser Permanente) raise a compelling question: can fecal immunochemical testing (FIT) be used beyond colorectal cancer (CRC) screening — to guide colonoscopy decisions in patients with GI symptoms?
-
Advancing Liver Cancer Treatment: A Cross-Border Dialogue with Dr. Qin Shukui and Dr. Pablo Sarobe
Liver cancer remains one of the deadliest malignancies worldwide, with China carrying a significant burden of cases. Understanding the unique epidemiology, molecular characteristics, and treatment strategies across different regions is crucial for advancing patient outcomes. In an exclusive cross-border dialogue, Professor Qin Shukui of Nanjing Tianyin Mountain Hospital, China, and Professor Pablo Sarobe of the…
-
Dr. Kefeng Ding: Exploration of the Balance between Radical Resection and Functional Preservation in Colorectal Cancer Treatment with LISH Procedure| Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee
At the 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee, Dr. Kefeng Ding from The Second Affiliated Hospital Zhejiang University School of Medicine presented innovative advancements in laparoscopic ileocecal-sparing hemicolectomy (LISH) for right-sided colon cancer, highlighting its potential to balance oncologic radicality with functional preservation. His insights provide valuable guidance for…
-
Dr. Xiujuan Qu: Breakthroughs in Precision Treatment for Advanced Colorectal Cancer – KRAS G12C Inhibitors Leading the Way
With the discovery of molecular targets and the development of corresponding targeted inhibitors, the treatment of metastatic colorectal cancer (mCRC) is becoming increasingly precise and personalized. At the recent 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee, Dr. Xiujuan Qu from The First Hospital of China Medical University shared the latest…
-
Trastuzumab Deruxtecan in HER2+ Advanced Breast Cancer
New findings from the DESTINY-Breast12 study, published in Nature Medicine on September 13, 2024, highlight the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (mBC), including patients with…
-
Patient Experience in Low-Risk DCIS: Insights from the COMET Trial
New insights from the COMET randomized clinical trial, published on December 12, 2024, in JAMA Oncology, offer important evidence on the patient experience in managing low-risk ductal carcinoma in situ…
-
New Hope for Drug-Resistant TB: MBLA Outperforms Xpert in Predicting Treatment Success
A new study published in the Journal of Infection reveals that the Molecular Bacterial Load Assay (MBLA) provides a faster and more accurate way to monitor treatment response in patients with pre-XDR/XDR-TB, compared to the widely used GeneXpert Ultra MTB/RIF test.
-
Dr. Andrea Mastrangelo Explores Unique CD8 T Cell Responses in HIV Controllers | hashtag CROI2025
New research led by Dr. Andrea Mastrangelo at Centre Hospitalier Universitaire Vaudois unveils a distinct transcriptomic signature in lymph node (LN) HIV-specific CD8 T cells of HIV controllers. Unlike chronic HIV-infected individuals (CHI), controllers exhibited an enriched population of stem-like CD8 T cells marked by TCF7, IL7R, and BACH2, which may contribute to proliferative potential…
Connecting Medical Expertise through Media